-
Disease Description
Type 1 diabetes mellitus is a medical condition that occurs when the pancreas, an organ in the abdomen, produces very little or no insulin. Insulin, a hormone that helps the body to absorb and use glucose (sugar). Without insulin, blood glucose levels become higher than normal.
Type 1 diabetes mos often develops when the immune system destroys the insulin-producing cells (beta-cells) in the pancreas. This is called an autoimmune response. The cause of this abnormal immune response is still not completely understood.
This process can take time to occur, and initially there may be no symptoms of diabetes. High blood sugar and its associated symptoms (frequent urination, thirst) do not usually occur until more than 90 percent of the cells that make insulin have been destroyed. . Type 1 diabetes usually begins in childhood or young adulthood, but can develop at any age.
Type 1 diabetes can develop in people with a family history of type 1 diabetes, but it also develops in people with no family history of diabetes. In either case, people who develop diabetes have one or more genes that make them susceptible to the disease. Environmental factors, such as exposure to certain viruses and foods early in life, might trigger the autoimmune response. [1]
Prevalence
In 2012, 29.1 million Americans, or 9.3% of the population, had diabetes. Diabetes remains the 7th leading cause of death in the United States in 2010. In the United States, Canada, and Europe, type 1 diabetes accounts for 5 to 10 percent of all cases of diabetes [1]
Current Treatment Options
Insulin treatment is one component of a diabetes treatment plan for people with type 1 diabetes. Insulin treatment replaces the body's own insulin, and aims to restore normal or near-normal blood sugar levels. With a little extra planning, people with diabetes who take insulin can lead a full life and keep their blood sugar under control.[1]
Evidence for and Proposed Mechanism for Cannabinoid Therapies
It was found that CBD treatment of 6- to 12-week-old mice significantly reduces the incidence of diabetes from 86% in nontreated control mice to 30% in CBD-treated mice. Results indicated that CBD can inhibit and delay destructive insulitis and inflammatory Th1-associated cytokine production in mice, resulting in a decreased incidence of diabetes possibly through an immunomodulatory mechanism shifting the immune response.[2] Research strengthens the previous assumption that CBD, known to be safe in humans, can possibly be used as a therapeutic agent for treatment of type 1 diabetes.[2]
1. UpToDate online resource
2. Weiss L, Zeira M, Reich S et al (2006) Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39:143–151
-
Category
Critical Ailments -
Created
Thursday, 16 March 2017 -
Group admin
CBIS
American States University
*** Warning this document contains graphic images.
Click the Below Image to Review our Cancer Drug Comparables
1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
*** PLUS
(3) other Cannabis Science
REAL WORLD Successes:
Stage 4 Breast Cancer
Skin Cancer
Karposis Sarcoma
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Photos
Observational Studies
CSi-VIP & CBIS-Shareholder Legacy
Click the ABOVE Image to Review our 1-Million Strong FC, Media Kit
*** Warning this document contains exciting images. 
Please Click the above image for information to become a CSi-VIP & CSi-VIP Legacy Cancer Drug Owner
Pease Click the Calendar image to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".
Click the above Image to become one of the First 1-Million Strong Killing Cancers, Fight Club Members to help 'Make that Change' Join in Now! *** Warning this Membership contains Exciting Results.
PS ... ALL of our CSi-VIP's and those who Donated through the ASU/CSi-EDP GO-Fund-Me Promotion you do not need to purchase anything, you are ALREADY included in the "First" 1-Million Membership Club, CONGRATULATIONS !!!
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 2024, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2025 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2025
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,839,095,296
Fully Diluted:
4,510,547,648
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
Activity Stream
CONGRATULATIONS Guys! We are about to go LIVE! We are launching a very exciting New Chapter in our Journey! We are launching a very ambitious... Show more
-
-
3-
-
-
5-
1-
2